Page last updated: 2024-12-06

5'-palmitoyl cytarabine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID41566
CHEMBL ID3350506
SCHEMBL ID3828257
MeSH IDM0052892

Synonyms (20)

Synonym
55726-45-9
brn 0727729
n(4)-palmitoyl cytarabine
1-beta-d-arabinofuranosyl-n(sup 4)-palmitoylcytosine
n(sup 4)-palmitoyl-1-beta-d-arabinofuranosylcytosine
cytosine, 1-beta-d-arabinofuranosyl-n(sup 4)-palmitoyl-
n-[1-[(2r,3s,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]hexadecanamide
plac
o57a51je0d ,
unii-o57a51je0d
nsc 250684
pl-ac
n4-palmitoyl-1-beta-d-arabinofuranosylcytosine
n4-palmitoyl-1-.beta.-d-arabinofuranosylcytosine
n4-palmitoyl cytarabine
XEFNBUBDJCJOGM-OUJCMCIWSA-N
n4 -palmitoyl-1-beta-d-arabinofuranosylcytosine
SCHEMBL3828257
CHEMBL3350506
Q27285356

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" No clear daily dose-response was noted."( [Treatment of myelodysplastic syndromes (MDS) with oral administration of N4-palmitoyl-1-beta-D-arabinofuranosyl cytosine (PLAC)].
Kimura, K; Ohno, R, 1988
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID96841Antitumor activity was determined against the ip implanted L1210 leukemia in mice by range in survival days at 200 mg/kg (treatment of 1qd schedule) dosage; Range is 14-231986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID96549Antitumor activity was determined against the ip implanted L1210 leukemia in mice by change in tumor weight at 200 mg/kg (treatment of 1qd schedule) dosage1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID153306Antitumor activity was determined against the ip implanted P388 leukemia in mice by percent median survival rate (treated/control) at 200 mg/kg (1 qd treatment schedule) dosage; >45.0/12.01986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID96701Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by range in survival days at 300 mg/kg (1 qd treatment schedule) dosage; Range is 14-181986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID98958Antitumor activity against the ip implanted L1210 leukemia in mice expressed as optimal dose (1 qd treatment schedule) required to produce greatest increase in life span was determined1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID152682Antitumor activity against the ip implanted P388 leukemia in mice expressed as optimal dose (1 qd treatment schedule) required to produce greatest increase in life span was determined1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID153000Antitumor activity was determined against the ip implanted P388 leukemia in mice by 45-day survivors in mice at 200 mg/kg (1 qd treatment schedule) dosage1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID97105Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by percent increase in life span at 300 mg/kg (1 qd treatment schedule) dosage1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID97224Antitumor activity against ip implanted L1210 leukemia in mice expressed as active dose range (1 qd treatment schedule) required to produce increase in life span by >25% was determined; Range is 100-2501986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID154854Antitumor activity was determined against the ip implanted P388 leukemia in mice by change in tumor weight at 200 mg/kg (1 qd treatment schedule) dosage1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID152822Antitumor activity was determined against the ip implanted P388 leukemia in mice by range in survival days at 200 mg/kg (1 qd treatment schedule) dosage; Range is 24->451986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID96543Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by change in tumor weight at 300 mg/kg (1 qd treatment schedule) dosage1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID97618Antitumor activity was determined against the ic implanted L1210 lymphoid leukemia in mice by percent median survival rate (treated/control) at 300 mg/kg (1 qd treatment schedule) dosage; 14.5/7.01986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID97288Antitumor activity was determined against the ip implanted L1210 leukemia in mice by 45-day survivors in mice at 200 mg/kg (treatment of 1qd schedule) dosage1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID97112Antitumor activity was determined against the ip implanted L1210 leukemia in mice by percent increase in life span at 200 mg/kg (treatment of 1qd schedule) dosage1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID97627Antitumor activity was determined against the ip implanted L1210 leukemia in mice by percent median survival rate (treated/control) at 200 mg/kg (treatment of 1qd schedule) dosage; 19.5/7.01986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID153284Antitumor activity was determined against the ip implanted P388 leukemia in mice by percent increase in life span at 200 mg/kg (1 qd treatment schedule) dosage1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID152368Antitumor activity against ip implanted P388 leukemia in mice expressed as active dose range (1 qd treatment schedule) required to produce increase in life span by >25% was determined; Range is 200-3001986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
AID100492Antitumor activity against the ic implanted L1210 lymphoid leukemia in mice expressed as optimal dose (1 qd treatment schedule) required to produce greatest increase in life span was determined1986Journal of medicinal chemistry, Oct, Volume: 29, Issue:10
Nucleoside conjugates. 7. Synthesis and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugates of ether lipids.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-199012 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (8.33%)5.53%
Reviews1 (8.33%)6.00%
Case Studies1 (8.33%)4.05%
Observational0 (0.00%)0.25%
Other9 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]